Arch Biopartners Inc (ACHFF)
1.23
-0.02
(-1.60%)
USD |
OTCM |
May 31, 16:00
Arch Biopartners Enterprise Value: 80.76M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 80.76M |
| May 30, 2024 | 82.01M |
| May 29, 2024 | 80.13M |
| May 28, 2024 | 80.76M |
| May 24, 2024 | 80.88M |
| May 23, 2024 | 80.76M |
| May 22, 2024 | 81.39M |
| May 21, 2024 | 80.13M |
| May 20, 2024 | 76.49M |
| May 17, 2024 | 80.76M |
| May 16, 2024 | 81.70M |
| May 15, 2024 | 83.90M |
| May 14, 2024 | 83.27M |
| May 13, 2024 | 82.01M |
| May 10, 2024 | 82.01M |
| May 09, 2024 | 81.39M |
| May 08, 2024 | 82.01M |
| May 07, 2024 | 82.01M |
| May 06, 2024 | 83.27M |
| May 03, 2024 | 84.52M |
| May 02, 2024 | 85.15M |
| May 01, 2024 | 83.90M |
| April 30, 2024 | 84.52M |
| April 29, 2024 | 88.35M |
| April 26, 2024 | 91.80M |
| Date | Value |
|---|---|
| April 25, 2024 | 97.70M |
| April 24, 2024 | 100.84M |
| April 23, 2024 | 105.23M |
| April 22, 2024 | 109.94M |
| April 19, 2024 | 112.14M |
| April 18, 2024 | 112.14M |
| April 17, 2024 | 111.51M |
| April 16, 2024 | 111.51M |
| April 15, 2024 | 110.25M |
| April 12, 2024 | 111.51M |
| April 11, 2024 | 112.14M |
| April 10, 2024 | 112.14M |
| April 09, 2024 | 114.65M |
| April 08, 2024 | 113.39M |
| April 05, 2024 | 113.39M |
| April 04, 2024 | 114.33M |
| April 03, 2024 | 114.65M |
| April 02, 2024 | 114.65M |
| April 01, 2024 | 110.88M |
| March 28, 2024 | 107.12M |
| March 27, 2024 | 105.86M |
| March 26, 2024 | 113.39M |
| March 25, 2024 | 116.15M |
| March 22, 2024 | 116.60M |
| March 21, 2024 | 117.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
33.92M
Minimum
Mar 18 2020
238.67M
Maximum
Dec 06 2021
94.42M
Average
73.44M
Median
Sep 11 2023
Enterprise Value Benchmarks
| Acasti Pharma Inc | 0.5379M |
| Aurinia Pharmaceuticals Inc | 424.68M |
| Edesa Biotech Inc | 11.48M |
| Lexaria Bioscience Corp | 45.09M |
| Xenon Pharmaceuticals Inc | 2.175B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.5754M |
| Total Expenses (Quarterly) | 0.5166M |
| EPS Diluted (Quarterly) | -0.0095 |
| Earnings Yield | -1.86% |
| Normalized Earnings Yield | -4.622 |